Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2023 | $6.00 | Outperform | RBC Capital Mkts |
| 4/21/2023 | $8.00 | Buy | The Benchmark Company |
| 4/13/2023 | $10.00 | Buy | Craig Hallum |
| 2/22/2023 | $10.00 | Outperform | Cowen |
| 2/13/2023 | $11.00 | Buy | H.C. Wainwright |
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
Conference Call Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance. "OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidance," stated Matt Foehr, Chief Executive Officer of OmniAb. "Continued progression of partner programs highlights the value of our technology platform and positions our business wel
OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in three investor conferences over the coming weeks. H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, May 6. Management will participate in a fireside chat on Wednesday, May 6th. Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28. Management will hold virtual one-on-one and small group meetings with investors on Thursday, May 28th. Jefferies Global Healthcare Conference, June 2-4 at the Marriott Marquis in New York City. Management will present a corporate overview on Wednesday, June 3rd at 4:55 p.m. Eastern time and will hold one-on-one meetings with investors
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on Thursday, May 7, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss first quarter 2026 financial results and business updates Date: Thursday, May 7, 2026 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (833) 461-5787 Internati
10-Q - OmniAb, Inc. (0001846253) (Filer)
8-K - OmniAb, Inc. (0001846253) (Filer)
DEF 14A - OmniAb, Inc. (0001846253) (Filer)
RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00
The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00
Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
Conference Call Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance. "OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidance," stated Matt Foehr, Chief Executive Officer of OmniAb. "Continued progression of partner programs highlights the value of our technology platform and positions our business wel
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on Thursday, May 7, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss first quarter 2026 financial results and business updates Date: Thursday, May 7, 2026 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (833) 461-5787 Internati
Conference Call Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. "OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, several later-stage assets are emerging with potential to generate meaningful milestones and, ultimately, recurring royalty revenue," said Matt Foehr, Chief Executive Officer of Omn
OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our
SC 13G/A - OmniAb, Inc. (0001846253) (Subject)
SC 13D/A - OmniAb, Inc. (0001846253) (Subject)